Kinnate Biopharma Inc has a consensus price target of $10.84, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from Stifel, Wedbush, and Jefferies on February 26, 2024, January 17, 2024, and September 19, 2023. With an average price target of $2.2 between Stifel, Wedbush, and Jefferies, there's an implied -17.73% downside for Kinnate Biopharma Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/26/2024 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | -3% | Stifel | Benjamin Burnett | $1.5 → $2.59 | Maintains | Hold | Get Alert |
01/17/2024 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | -25.1% | Wedbush | David Nierengarten | → $2 | Reiterates | Neutral → Neutral | Get Alert |
09/19/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | -25.1% | Jefferies | Roger Song | $31 → $2 | Maintains | Buy | Get Alert |
09/19/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | -25.1% | Wedbush | David Nierengarten | $14 → $2 | Downgrade | Outperform → Neutral | Get Alert |
09/19/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | — | HC Wainwright & Co. | Robert Burns | — | Downgrade | Buy → Neutral | Get Alert |
09/19/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 49.8% | Piper Sandler | Christopher Raymond | $20 → $4 | Downgrade | Overweight → Neutral | Get Alert |
08/15/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 798.81% | HC Wainwright & Co. | Robert Burns | → $24 | Reiterates | Buy → Buy | Get Alert |
06/08/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 798.81% | HC Wainwright & Co. | Robert Burns | → $24 | Reiterates | Buy → Buy | Get Alert |
05/18/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 798.81% | HC Wainwright & Co. | Robert Burns | $25 → $24 | Maintains | Buy | Get Alert |
05/12/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 424.31% | Wedbush | David Nierengarten | → $14 | Reiterates | Outperform → Outperform | Get Alert |
05/12/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 102.23% | Stifel | Benjamin Burnett | $5 → $5.4 | Maintains | Hold | Get Alert |
04/20/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 836.26% | HC Wainwright & Co. | Robert Burns | $33 → $25 | Maintains | Buy | Get Alert |
04/19/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 873.71% | Goldman Sachs | Paul Choi | $29 → $26 | Maintains | Buy | Get Alert |
04/18/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 873.71% | Goldman Sachs | Paul Choi | $29 → $26 | Maintains | Buy | Get Alert |
03/20/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 1135.86% | HC Wainwright & Co. | Robert Burns | → $33 | Reiterates | → Buy | Get Alert |
03/16/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 199.6% | Stifel | Benjamin Burnett | $11 → $8 | Maintains | Hold | Get Alert |
03/16/2023 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 836.26% | Wedbush | David Nierengarten | $29 → $25 | Maintains | Outperform | Get Alert |
11/17/2022 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 311.95% | Stifel | Benjamin Burnett | $35 → $11 | Downgrade | Buy → Hold | Get Alert |
07/28/2022 | KNTE | Buy Now | Kinnate Biopharma | $2.67 | 1135.86% | HC Wainwright & Co. | Robert Burns | → $33 | Initiates | → Buy | Get Alert |
The latest price target for Kinnate Biopharma (NASDAQ: KNTE) was reported by Stifel on February 26, 2024. The analyst firm set a price target for $2.59 expecting KNTE to fall to within 12 months (a possible -3.00% downside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for Kinnate Biopharma (NASDAQ: KNTE) was provided by Stifel, and Kinnate Biopharma maintained their hold rating.
There is no last upgrade for Kinnate Biopharma.
The last downgrade for Kinnate Biopharma Inc happened on September 19, 2023 when Wedbush changed their price target from $14 to $2 for Kinnate Biopharma Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kinnate Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kinnate Biopharma was filed on February 26, 2024 so you should expect the next rating to be made available sometime around February 26, 2025.
While ratings are subjective and will change, the latest Kinnate Biopharma (KNTE) rating was a maintained with a price target of $1.50 to $2.59. The current price Kinnate Biopharma (KNTE) is trading at is $2.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.